Sep 27, 2021
Aciclovir
seen from Bolivia
seen from China
seen from Philippines
seen from South Korea
seen from Bangladesh
seen from Brazil
seen from United States
seen from China
seen from Yemen
seen from Netherlands
seen from United States
seen from United States
seen from China
seen from Yemen
seen from Guatemala
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
Aciclovir
acetanilide; prodrug of paracetamol
my first synthesis of a prodrug + working on lab reports as always
Amphetamine x Ecstasy
I guess it's just my life and I can take it if I wanna.
Prodrugs Design | Chapter 11 | Modern Advances in Pharmaceutical Research Vol. 2
Prodrug design can be used in the following cases: improving active drug solubility and consequently bioavailability, increasing permeability and absorption and modifying the drug’s distribution profile. In the prodrug design, a computational approach consisting of calculations using Molecular Orbital (MO) and Molecular Mechanics (MM) methods and correlations between experimental and calculated values can be utilized.
Author(s) Details
Professor Rafik Karaman Department of Bioorganic Chemistry, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine and Department of Sciences, University of Basilicata, Viadell’Ateneo Lucano 10, 85100, Potenza, Italy.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/85/1204/847-1
View Volume: https://doi.org/10.9734/bpi/mapr/v2
The Question of Prodrug Naming | Chapter 07 | Modern Advances in Pharmaceutical Research Vol. 2
Prodrug is a term used to define a pharmacologically inactive chemical entity that can be used to temporarily alter the physicochemical properties of a drug to increase its usefulness and decrease its associated toxicity. According to the definition, the inactive prodrug converts to its active parent drug and a non-toxic linker upon exposure to a physiological environment. Albert stated in his Selective Toxicity book, that the term prodrug is incorrect and should be replaced with the term predug. He apologized for having invented the term, however, now it is too widely used to alter.
Author(s) Details
Professor Rafik Karaman Department of Bioorganic Chemistry, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine and Department of Sciences, University of Basilicata, Viadell’Ateneo Lucano 10, 85100, Potenza, Italy.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/85/1200/843-1
View Volume: https://doi.org/10.9734/bpi/mapr/v2
Prodrugs Designed by DFT and Molecular Mechanics Methods | Chapter 05 | Modern Advances in Pharmaceutical Research Vol. 2
The accumulation of knowledge on intramolecular processes, enzymes and transporters along with the vast progress in molecular revolution have accelerated the search for prodrugs having the capability to replace their corresponding current marketed drugs and to provide therapeutics with better pharmacological profiles. Utilizing the different available computational methods has led to the design and synthesis of a variety of prodrugs to replace their corresponding parent drugs.
It has been proven that prodrugs can significantly improve the life quality of patients.
The directed enzyme prodrug therapy (DEPT) approach to employ the design of artificial enzymes to activate prodrugs at specific sites along with use of intramolecular processes to design prodrugs are the most attractive strategies to obtain more efficient therapeutics.
Author(s) Details
Professor Rafik Karaman Department of Bioorganic Chemistry, Faculty of Pharmacy, Al-Quds University, P.O.Box 20002, Jerusalem, Palestine and Department of Sciences, University of Basilicata, Via dell’ateneo Lucano 10, 85100, Potenza, Italy.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/85/1198/841-1
View Volume: https://doi.org/10.9734/bpi/mapr/v2
The Future of Prodrugs Design | Chapter 03 | Modern Advances in Pharmaceutical Research Vol. 2
When knowledge fails to provide answers to important questions such as how to improve the bioavailability of vital medications, “Imagination is more important than knowledge,” as Albert Einstein once said. Ingenuity in the design of effective prodrugs has been lacking in quantity and quality. The reasons behind the low quality of ingenuity could be related to the fact that medicinal chemists have expertise in organic and organometalic chemistry not in biochemistry and biology. On the other hand, pharmaceutical chemists, biologists and biochemists do not have the expertise to make sophisticated chemical devices. Therefore, in order for a prodrug strategy to work, a team consisting of all this expertise is necessary.
Author(s) Details
Professor Rafik Karaman Department of Bioorganic Chemistry, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine and Department of Sciences, University of Basilicata, Viadell’Ateneo Lucano 10, 85100, Potenza, Italy.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/85/1196/839-1
View Volume: https://doi.org/10.9734/bpi/mapr/v2